Iterum Therapeutics Plc’s recently made public that its Director Dunne Michael W. acquired Company’s shares for reported $35000.0 on Dec 22 ’23. In the deal valued at $1.40 per share,25,000 shares were bought. As a result of this transaction, Dunne Michael W. now holds 113,754 shares worth roughly $0.16 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Dunne Michael W. bought 10,000 shares, generating $18,442 in total proceeds. Upon buying the shares at $1.84, the Director now owns 88,754 shares.
Before that, Dunne Michael W. bought 20,000 shares. Iterum Therapeutics Plc shares valued at $40,690 were divested by the Director at a price of $2.03 per share. As a result of the transaction, Dunne Michael W. now holds 78,754 shares, worth roughly $0.11 million.
Gabelli & Co upgraded its Iterum Therapeutics Plc [ITRM] rating to a Hold from a a Sell in a research note published recently. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who increased its forecast for the stock in mid March from “a Neutral” to “a Buy”. RBC Capital Mkts also remained covering ITRM and has decreased its forecast on June 02, 2020 with a “Sector perform” recommendation from previously “an Outperform” rating. Gabelli & Co revised its rating on January 21, 2020. It rated ITRM as “a Sell” which previously was an “a Buy”.
Price Performance Review of ITRM
On Tuesday, Iterum Therapeutics Plc [NASDAQ:ITRM] saw its stock jump 1.40% to $1.45. Over the last five days, the stock has gained 34.26%. Iterum Therapeutics Plc shares have fallen nearly -26.40% since the year began. Nevertheless, the stocks have risen 116.42% over the past one year. While a 52-week high of $2.50 was reached on 01/30/24, a 52-week low of $0.64 was recorded on 10/10/24. SMA at 50 days reached $1.1181, while 200 days put it at $1.3624.
Levels Of Support And Resistance For ITRM Stock
The 24-hour chart illustrates a support level at 1.4067, which if violated will result in even more drops to 1.3633. On the upside, there is a resistance level at 1.5167. A further resistance level may holdings at 1.5833. The Relative Strength Index (RSI) on the 14-day chart is 60.18, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.4131, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 57.54%. Stochastics %K at 51.50% indicates the stock is a holding.
How much short interest is there in Iterum Therapeutics Plc?
A steep rise in short interest was recorded in Iterum Therapeutics Plc stocks on 2024-10-15, dropping by -0.13 million shares to a total of 0.21 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-13 was 0.34 million shares. There was a decline of -59.75%, which implies that there is a negative sentiment for the stock.
